About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

AstraZeneca Reps Seem Resigned to the Inevitable as Details Emerge of Buyout Package

By Jim Edwards | Oct 20, 2009

AstraZeneca sales reps are reacting with relative calm to the news that they will all be offered buyouts as the company attampts to figure out how many will be laid off if too few take the package. A glance at CafePharma’s message boards shows that aside from the usual clowns, the staff seem to understand that layoffs are inevitable at a company that has $620 million in outstanding legal liabilities and shown only modest gains in its existing “Enhancing Productivity” program.

News of the buyouts broke on Pharmalot:

“AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are interested in leaving the company. We will know the full scope of the changes in the coming weeks.”

Here’s a sampling of the reaction from the field:

  • this cut is going to take a good chop at middle management, especially managers in RPT and Hospital, as well as RSM’s. Certainly the first of more cuts to come. It’s kind of strange when you’re working with your manager, who on one hand is rating you and asking you to stay focused on the metrics, and on the other scared shitless for their job.
  • Geez, this is a freaking nightmare. Everywhere I look it’s layoffs. I have to give props to AZ for offering this buyout -I guarantee you that the folks over at Wyeth would have loved that opportunity, and they didn’t get it.
  • I have heard 2 weeks for every year of service with AZ, plus 1 week. So, a rep with 10 years would receive 21 weeks paid.There will be a minimum of 12 weeks for those with less years of service. I have heard RSD’s are getting their notice this week. DSM’s will be informed the week of the 26th. The following week PSS’s will be notified. (first week in November)
  • 3 weeks for band 5 - 6. DSM and RSD. The rest is correct.
  • Yep, at least you can start planning now. I had my family in from all over the country and was telling them how much I really loved where I was at and would love to be there for a long time……..then I check my voicemail!!!
  • There have been literally thousands of posts here on CP about how much we have suffered as a company from poor management. We told them the Tablet PC/TSi was a sales killer and they refused to listen. They hired reps and put them into 3 person microterritories and we told them they were not needed. They forced us to spend millions on LBX programs with very little return, and they still do. Now we are laying off people. My guess is that a lot of the “bad ones” survive and a lot of good ones get let go. That’s usually how it goes.

    I think the entire sales org. realizes that this downsizing will be repeated yearly for many years to come. The industry is headed for very difficult times. It is now the world of generics that control all.

  • I am a DSM in Minnesota and we begged them not to make us hire more PSSs because access was low and we were tripping over each other, but the ASDs would not listen even in the rare time when we could convince our RSD. The smug ASDs continued to demand timely hiring (the diversity thing flew out the window - not waiting for the right pool, just get a warm body in there) so we could deliver the call metrics. Now we are laying off and getting to the number of PSSs we recommended years ago.

Related:

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • AstraZeneca sales force gets buyout offer

    Fierce Pharma - 36 days 2 hours 4 minutes ago

    AstraZeneca is offering buyouts to its entire sales force. Yep, you read that right. Pharmalot reports that the U.K.-based drugmaker asked its reps to "self-identify" whether they'd prefer to leave the company with a severance package or stick around. Presumably the company is counting on some portion of its sales force to exit. The question...

  • AZ Call Notes Expose Secret Life of Seroquel Reps ... And It's Mostly Scandal-Free

    BNET Pharma - 62 days 1 hour 8 minutes ago

    The release of AstraZeneca's sales rep call notes in the Seroquel litigation is mostly good news for the company. Bloomberg highlighted some grim

  • Note to AZ: Cut 500, grow EPS by 5 cents

    Fierce Pharma - 27 days 1 hour 22 minutes ago

    Less than two weeks ago, we learned that AstraZeneca was offering buyout packages to all of its sales reps. As yet we still don't know exactly how much of its sales force the drugmaker hopes to shed. But thanks to some calculator-packing analysts, we do know how much the company could benefit financially. Leerink Swann analysts put their pencils...

  • The Associated Press: Drugmaker AstraZeneca cutting its US sales force

    PharmaGossip - 35 days 10 hours 52 minutes ago

    Drugmaker AstraZeneca cutting its US sales force (AP) – 9 hours ago WILMINGTON, Del. — British drugmaker AstraZeneca PLC plans to cut its U.S. sales force by offering buyouts. The maker of cholesterol pill Crestor and anti-psychotic drug Seroquel is asking interested sales representatives to identify themselves. AstraZeneca last week...

  • AstraZeneca stock surges on deal talk

    Fierce Pharma - 56 days 58 minutes ago

    No sooner is one M&A deal agreed upon than market-watchers start speculating about the next. This time, it's AstraZeneca (AZN) in their sights, and the company's shares jumped in the U.K. on buyout talk. The word on the street is that Novartis (NVS) might soon be knocking on AstraZeneca's door with a buyout offer in hand. Pharma is in the midst...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement